Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

ABSTRACT:

Background

To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC inhibitor.

Methods

In phase 1, 16 men received dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m(2) every 21 days. In phase 2, 30 additional men received dasatinib 100 mg once daily/docetaxel 75 mg/m(2) every 21 days. Efficacy endpoints included changes in prostate-specific antigen (PSA), measurable disease, bone scans, and markers of bone metabolism. Safety and pharmacokinetics were also studied.

Results

Combination dasatinib and docetaxel therapy was generally well tolerated. Thirteen of 46 patients (28%) ha

SUBMITTER: Araujo JC 

PROVIDER: S-EPMC3898168 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature